⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure S2 from Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression

Audrey Laroche‐Clary Vanessa Chaire Veronica Valverde Marie‐Alix Derieppe Antoîne Italiano

View Full Paper

Ask AI

Bookmark

Share

Key Points

The presence of ATM expression, assessed through western blotting, indicates a potential role in treatment response.
Supplementary data highlights that IB202 exhibits no ATM expression, which could influence therapeutic strategies.
Lurbinectedin treatment combined with ATR inhibition shows promise in soft-tissue sarcomas, particularly influenced by SLFN11 levels.
Findings suggest that SLFN11 may serve as a valuable biomarker for predicting response in sarcoma treatments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Supplementary figure shows ATM expression in soft-tissue sarcomas, highlighting SLFN11's predictive role.

Abstract

Fig 2 supplementary: pATM/ATM western blotting in IB144 and IB202, there is no expression of ATM in IB202

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Laroche‐Clary et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f57a https://doi.org/10.1158/1078-0432.30029351

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression2025
2Supplementary Figure S3 from Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression2025
3Data from Synergistic Effects of ATR Inhibition and Lurbinectedin in Soft-Tissue Sarcomas: The Predictive Role of SLFN11 Expression2025
4Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
5Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
6Supplementary Figure 12 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
7Supplementary Figure 12 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024
8Supplementary Figure 13 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer2024